USX:TTOO - T2 Biosystems Inc (USD 0.486) T2 Biosystems Inc
Sector: Health Technology, Industry: Medical Specialties
Add to Watchlist
   


Yahoo Finance

USD 0.4859    -0.024 (-4.73%)
Show Basic Chart | 3M    6M    1Y    3Y    5Y          

9 Apr 2020


Overview

9 Apr 2020

Day Change: -0.024 (-4.73%)

52 Wk Range: 0.235 - 3.21

Day's Range: 0.46 - 0.5199

Last Volume: 7,005,437

Current Yield: 0%

Projected Yield: 0%

Open: USD 0.47

9 Apr 2020

Metric TTOO S.Median
Beta 0.99 0.84
VaR 78.79 25.23
E.Shortfall 129.83 45.03
Liquidity 3.1M 95.2K

Fundamental

9 Apr 2020

PE: -0.374

Market Cap: 22.1M

Price Over Book: -0.649

Price Over Sales: 2.65

Return On Assets: -207.1%

Return On Equity: 173.5%

Price Over NAV: [Friends Only]

General

CEO: John P. McDonough

Headquarters: Lexington

Employees: 153

Sector: Health Technology

Industry: Medical Specialties

Useful Links
Homepage

Description

T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States. It provides T2 Magnetic Resonance platform that enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, and urine. The company also offers T2Dx, a bench-top instrument for sepsis, Lyme disease, and other applications, as well as T2Candida panel for the detection of candida species in human whole blood specimens. In addition, it is developing T2Bacteria, a multiplex diagnostic panel that detects various bacterial pathogens associated with sepsis; T2Lyme for the detection of various strains of Lyme disease-causing bacteria; and T2Plex, an integrated instrument for hemostasis applications, as well as T2HemoStat panel, a panel of diagnostic tests that can provide data across the hemostasis spectrum, including measurements of fibrinogen, platelet activity, and clot lysis. The company has collaboration agreement with Canon U.S. Life Sciences, Inc. to develop a novel diagnostic test panel to detect Lyme disease, a tick-borne illness; and Allergan Sales, LLC for the direct detection diagnostic test panel that adds additional bacteria species to the existing T2Bacteria product candidate and testing drug resistance directly in whole blood. T2 Biosystems, Inc. was founded in 2006 and is headquartered in Lexington, Massachusetts.